What Google's health targeting rules actually forbid

What Google classifies as sensitive health

Google's personalized advertising policy defines Health as a sensitive interest category. The definition is broader than most practices assume, and reading it in full is worth five minutes.

It covers physical or mental health conditions, including sexual health and chronic conditions that require long-term care or management. It covers products, services or procedures to treat or manage chronic conditions, including over-the-counter medications and medical devices. It covers any health issue associated with intimate body parts or functions. It covers disabilities, even where the content is aimed at a caretaker rather than the person.

And it covers invasive medical procedures, including cosmetic surgery, surgical procedures, or injections.

That final clause is the one that captures an entire industry. A practice selling neuromodulator or dermal filler treatments is advertising injections. It does not matter that the treatment is elective, that it is paid for in cash, that no insurance is billed, or that the business markets itself as aesthetic rather than medical. The policy is written around the procedure being advertised.

Exactly which targeting features are removed

Google splits targeting into two groups and applies the restriction to one of them.

Advertiser-curated audiences cannot be used when promoting in a sensitive interest category, because Google's stated reason is that they may inadvertently contain sensitive user signals. That group is: Customer Match, your data segments, audience expansion, and lookalike segments.

Predefined Google audiences can be used, because the sensitive signals are automatically excluded from them. That group is: in-market segments, affinity, demographics and detailed demographics (each with exceptions), life events, location targeting, and custom segments.

So the entire first-party-data motion is closed. No uploading the patient list. No lookalike built from people who booked. No expanding an audience that performed. Remarketing to someone who viewed a treatment page is the same restriction wearing a different name, because it is your data segment either way.

What this does to the pitch you have probably heard

A recurring proposal to aesthetics practices is that the patient list is an untapped advertising asset: upload it, build a lookalike, find more people like your best patients. In most verticals that is sound advice and it works.

Here it is against policy, and it has been for some time. An agency proposing it is either not reading the policy or is assuming nobody will check. Either is a reason to ask more questions.

The same applies to any tool promising to match your CRM into a health-vertical ad account for targeting purposes. The restriction is at the platform, not at the integration.

What is still worth doing

Custom segments are the most useful thing on the permitted list, because they are assembled from search behaviour and interests rather than from a list of identified people. Built around the terms a considering patient actually uses, they do real work.

In-market segments and life events are genuine and usable. Location targeting is untouched, which matters disproportionately for a practice whose realistic catchment is a thirty minute drive.

None of that replaces a patient list, and it is worth saying so plainly rather than presenting the alternative as equivalent. An account in this category leans harder on query intent and lighter on audience precision than an account in an unrestricted vertical. That is a structural property of the category, not a deficiency in somebody's setup.

The consequence most accounts have not absorbed

Remove the audience layer and the remaining levers are the query, the creative, the landing page, and the conversion you report back to the platform.

In an unrestricted account, a well-built audience partly compensates for a weak conversion definition. Here nothing compensates. Whatever you count is what the bidding will go and find more of, with no audience constraint to catch the error.

That is why an aesthetics account optimizing toward a raw form fill degrades faster than the same mistake elsewhere. Conversions look healthy, cost per lead holds, and the front desk quietly reports that half the enquiries were never going to book. The fix is to optimize toward the strongest event the booking volume can actually support, usually a booked or attended consultation, and to report on the step below it.

Because the restriction applies to every competitor equally, the ability to feed real outcomes back to the platform stops being a best practice and becomes the main axis of competition in the category.

The 2025 clarification, and who it helps

In May 2025 Google updated the Health sensitive interest category to clarify that it excludes content directed at healthcare professionals acting in their professional capacity, with a parallel change to Restricted Drug Terms effective 1 July 2025.

That is a real opening for the business-to-business side of the industry. A device manufacturer, a practice-management platform or a supplier marketing to clinicians is not in the same position as a practice marketing to patients.

It changes nothing for consumer-facing aesthetics advertising, and it should not be quoted as though it did.

How to check your own account

Open the account and list what each campaign is actually targeting. If a Customer Match list, a data segment, an audience expansion setting or a lookalike is attached to anything promoting a covered procedure, that is your finding, and in our experience it usually predates whoever is running the account now.

Then read the policy page itself rather than a summary of it, footnotes included. The exceptions on demographics and the treatment of custom segments are where the usable answers live, and Google maintains a change log for exactly this reason.

This page states what the policy says. It is not legal advice, and advertising rules for medical practices also come from state boards and other regulators that Google does not administer.

Targeting availability in a sensitive health category